Literature DB >> 17573598

What is a missed dose? Implications for construct validity and patient adherence.

A P Sankar1, D C Nevedal, S Neufeld, M R Luborsky.   

Abstract

The construct 'missed dose' is central to many assessments of medication adherence. However, few studies have investigated how patients or clinicians conceptualize missed doses or the extent of the concordance or discordance between clinicians and patients. To address this gap we conducted semi-structured interviews with 45 sero-positive African American adults taking HAART and 17 of their clinicians. Results reveal large variability in missed dose conceptions among both patients and physicians and significant differences between the two groups. Overall, patients reported a stricter definition of missed dose than did clinicians. Fifty-five percent of patients thought that a pill-taking delay of six hours beyond the prescribed dosing time constituted a missed dose, by comparison, only one physician agreed with this assessment. More than one-third of patients thought that the proper response to a missed dose would be to skip it altogether, but only about 12% of clinicians agreed. These findings have implications for the construct validity of self-report measures of adherence, for patient adherence behaviours based on missed dose conceptions and for patient-physician relationships and communication within the clinical environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573598      PMCID: PMC4214549          DOI: 10.1080/09540120600708501

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  16 in total

1.  Factors associated with accurate self-reported adherence to HIV antiretrovirals.

Authors:  Mina Kimmerling; Glenn Wagner; Bonnie Ghosh-Dastidar
Journal:  Int J STD AIDS       Date:  2003-04       Impact factor: 1.359

2.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06

3.  Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.

Authors:  Andrew R Moss; Judith A Hahn; Sharon Perry; Edwin D Charlebois; David Guzman; Richard A Clark; David R Bangsberg
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

4.  Barriers to antiretroviral adherence among HIV-infected adults.

Authors:  D A Murphy; K J Roberts; D J Martin; W Marelich; D Hoffman
Journal:  AIDS Patient Care STDS       Date:  2000-01       Impact factor: 5.078

5.  No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen.

Authors:  Loren G Miller; Carol E Golin; Honghu Liu; Ron D Hays; Jenna Hua; Neil S Wenger; Andrew H Kaplan
Journal:  J Infect Dis       Date:  2004-03-31       Impact factor: 5.226

6.  Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries.

Authors:  Glenn J Wagner
Journal:  AIDS Patient Care STDS       Date:  2002-12       Impact factor: 5.078

7.  The process of self-report of impairment in clinical research.

Authors:  M R Luborsky
Journal:  Soc Sci Med       Date:  1995-06       Impact factor: 4.634

8.  Factors associated with antiretroviral adherence among HIV-infected women with children.

Authors:  Debra A Murphy; Lisa Greenwell; Dannie Hoffman
Journal:  Women Health       Date:  2002

9.  Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men.

Authors:  P N Halkitis; J T Parsons; R J Wolitski; R H Remien
Journal:  AIDS Care       Date:  2003-02

10.  Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Authors:  Ajay K Sethi; David D Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant
Journal:  Clin Infect Dis       Date:  2003-09-19       Impact factor: 9.079

View more
  6 in total

1.  Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues.

Authors:  Cynthia R Pearson; Jane M Simoni; Peter Hoff; Ann E Kurth; Diane P Martin
Journal:  AIDS Behav       Date:  2007-03

Review 2.  How qualitative methods contribute to understanding combination antiretroviral therapy adherence.

Authors:  Andrea Sankar; Carol Golin; Jane M Simoni; Mark Luborsky; Cynthia Pearson
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

Review 3.  The impact of medication regimen factors on adherence to chronic treatment: a review of literature.

Authors:  Karen S Ingersoll; Jessye Cohen
Journal:  J Behav Med       Date:  2008-01-19

4.  What Time is it? Adherence to Antiretroviral Therapy in Ethiopia.

Authors:  Yordanos M Tiruneh; Ira B Wilson
Journal:  AIDS Behav       Date:  2016-11

5.  Should patients skip late doses of medication? A pharmacokinetic perspective.

Authors:  Elias D Clark; Sean D Lawley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-06-20       Impact factor: 2.410

6.  Oral antiviral treatments for COVID-19: opportunities and challenges.

Authors:  Laila Rahmah; Sunny O Abarikwu; Amanuel Godana Arero; Mickael Essouma; Aliyu Tijani Jibril; Andrzej Fal; Robert Flisiak; Rangarirai Makuku; Leander Marquez; Kawthar Mohamed; Lamin Ndow; Dorota Zarębska-Michaluk; Nima Rezaei; Piotr Rzymski
Journal:  Pharmacol Rep       Date:  2022-07-25       Impact factor: 3.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.